+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Europe Antibiotics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Drug Class; Action Mechanism; and Country

  • PDF Icon

    Report

  • 127 Pages
  • June 2020
  • Region: Europe
  • The Insight Partners
  • ID: 5116944
UP TO OFF until Jun 30th 2024
The European antibiotics market is expected to reach US$ 15,569.87 million by 2027 from US$ 12,457.70 million in 2019. The market is estimated to grow with a CAGR of 3.1% from 2020 to 2027.

The antibiotics market is growing primarily due to prevalence of infectious diseases and increasing development of generic drugs in The European region that are boosting the market over the years. Restraining factors, such as tedious and expensive process of antibiotic development is likely to slow down the growth of the market in the coming years. Additionally, growing investments to combat antimicrobial resistance and incorporation of novel computing technologies for antibiotics discovery are likely to increase the growth of the antibiotics market in the forecast period.

Antibiotics are medicines containing substances that are active against bacteria. These medicines either kill the bacteria or control the infection by inhibiting the bacterial reproduction, which in turn helps patient to recover. Antibiotics are specific to the type of bacteria being treated and are not able to be interchanged from one infection to another.

Bacterial infection refers to the proliferation of harmful bacterial strains on or inside the human body. These microorganisms can infect any part of the body and may lead to severe consequences. A few of the indications of bacterial infections include pneumonia, meningitis, and food poisoning. Moreover, several commonly occurring pediatric bacterial infections are acute otitis media (AOM), sinusitis, bronchitis, upper respiratory tract infection, and pharyngitis.

Generic versions are introduced in the market with an aim to offer cost-efficient drugs and increase the reach of these drugs to people belonging to different economic classes. Generic versions are popular due to their availability and affordability. Additionally, the companies are focusing on development of generic versions to offer antibiotics at minimal costs. Also, pressure to control pharmaceutical expenditure and price competition among pharmaceutical companies are fueling the development of generic medicines markets in Europe. Therefore, generic manufacturers with low production costs, broad portfolios, and stable supplies would witness a robust market growth. Thus, the above factors are likely to drive the growth of antibiotic market in the forecasted period.

Europe has been massively hit by COVID-19 outbreak affecting many of its countries on a large scale. Italy, Germany, Spain, the UK, and France along with other European countries are continually witnessing rise in number of COVID-19 cases every day. In March 2020, European Medicines Agency has formed an executive committee to deal with impact of COVID-19 on supply chain of medicines. According to a data published in a newsletter in March 2020, majority of the European pharmaceutical companies has its manufacturing facilities located in India, while an estimated 70% of the raw ingredients comes from China. This whole supply chain is likely to hamper due to industrial shutdowns, which will ultimately hamper the growth of the market.

In 2019, the cephalosporin segment accounted for the largest share of the market; it is further expected to continue its dominance during the forecast period. This class of antibiotics is usually safe due to low toxicity to self-cells and remarkable efficiency against susceptible bacteria. On the other hand, fluoroquinolones are expected to register the highest CAGR in the antibiotics market during 2020-2027.

Some of the significant secondary sources for antibiotics market included in the report are the World Health Organization (WHO), European Medicines Agency (EMA),and others.

Reasons to Buy:
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in The European Antibiotics Market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the regional Antibiotics market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth regional market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Table of Contents

1. Introduction
1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Antibiotics Market - By Drug Class
1.3.2 Europe Antibiotics Market - By Action Mechanism
1.3.3 Europe Antibiotics Market - By Country
2. Europe Antibiotics Market - Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Antibiotics Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Antibiotics Market - Europe PEST Analysis
4.3 Expert Opinion
5. Europe Antibiotics Market - Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Rising Prevalence of Bacterial Infections
5.1.2 Increasing Development of Generic Drugs
5.2 Key Market Restraints
5.2.1 Tedious and Expensive Process of Antibiotic Development
5.3 Market Opportunities
5.3.1 Growing Investments to Combat Antimicrobial Resistance
5.4 Future Trends
5.4.1 Incorporation of Novel Computing Technologies for Antibiotics Discovery
5.5 Impact analysis
6. Antibiotics Market - Europe Analysis
6.1 Europe Antibiotics Market Revenue Forecasts and Analysis
7. Europe Antibiotics Market Analysis And Forecasts To 2027 - By Drug Class
7.1 Overview
7.2 Europe Antibiotics market, By Drug Class 2019 & 2027 (%)
7.2.1 Europe Antibiotics Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
7.3 Sulfonamides
7.3.1 Overview
7.3.2 Europe Sulfonamides Market Revenue and Forecast to 2027 (US$ Mn)
7.4 Aminoglycosides
7.4.1 Overview
7.4.2 Europe Aminoglycosides Market Revenue and Forecasts to 2027 (US$ Mn)
7.5 Carbapenem
7.5.1 Overview
7.5.2 Europe Carbapenem Market Revenue and Forecasts to 2027 (US$ Mn)
7.6 Macrolides
7.6.1 Overview
7.6.2 Europe Macrolides Market Revenue and Forecasts to 2027 (US$ Mn)
7.7 Fluoroquinolones
7.7.1 Overview
7.7.2 Europe Fluoroquinolones Market Revenue and Forecasts to 2027 (US$ Mn)
7.8 Penicillin
7.8.1 Overview
7.8.2 Europe Penicillin Market Revenue and Forecasts to 2027 (US$ Mn)
7.9 Cephalosporins
7.9.1 Overview
7.9.2 Europe Cephalosporins Market Revenue and Forecasts to 2027 (US$ Mn)
7.10 Others
7.10.1 Overview
7.10.2 Europe Others Market Revenue and Forecasts to 2027 (US$ Mn)
8. Europe Antibiotics Market Analysis - By Action Mechanism
8.1 Overview
8.2 Europe Antibiotics Market, By Action Mechanism 2019-2027 (%)
8.2.1 Europe Antibiotics Market Revenue and Forecasts to 2027, By Action Mechanism (US$ Mn)
8.3 Mycolic Acid Inhibitors
8.3.1 Overview
8.3.2 Europe Mycolic Acid Inhibitors Market Revenue and Forecasts to 2027 (US$ Mn)
8.4 RNA Synthesis Inhibitors
8.4.1 Overview
8.4.2 Europe RNA Synthesis Inhibitors Market Revenue and Forecasts to 2027 (US$ Mn)
8.5 DNA Synthesis Inhibitors
8.5.1 Overview
8.5.2 Europe DNA Synthesis Inhibitors Market Revenue and Forecasts to 2027 (US$ Mn)
8.6 Protein Synthesis Inhibitors
8.6.1 Overview
8.6.2 Europe Protein Synthesis Inhibitors Market Revenue and Forecasts to 2027 (US$ Mn)
8.7 Cell Wall Synthesis Inhibitors
8.7.1 Overview
8.7.2 Europe Cell Wall Synthesis Inhibitors Market Revenue and Forecasts to 2027 (US$ Mn)
8.8 Others
8.8.1 Overview
8.8.2 Europe Others Market Revenue and Forecasts to 2027 (US$ Mn)
9. Antibiotics Market Revenue and Forecasts To 2027 - Geographical Analysis
9.1 Europe Antibiotics Market Revenue and Forecasts To 20
9.1.1 Overview
9.1.2 Europe: Antibiotics Market - Revenue and Forecast to 2027 (USD Million)
9.1.3 Europe: Antibiotics Market, by Drug Class, 2018-2027 (USD Million)
9.1.4 Europe: Antibiotics Market, by Action Mechanism, 2018-2027 (USD Million)
9.1.5 Europe: Antibiotics Market, by Country, 2018 & 2027 (%)
9.1.6 Germany: Antibiotics Market - Revenue and Forecast to 2027 (USD Million)
9.1.6.1 Germany: Antibiotics Market - Revenue and Forecast to 2027 (USD Million)
9.1.6.2 Germany: Antibiotics Market, by Drug Class, 2018-2027 (USD Million)
9.1.6.3 Germany: Antibiotics Market, by Action Mechanism, 2018-2027 (USD Million)
9.1.7 UK: Antibiotics Market - Revenue and Forecast to 2027 (USD Million)
9.1.7.1 UK: Antibiotics Market - Revenue and Forecast to 2027 (USD Million)
9.1.7.2 UK: Antibiotics Market, by Drug Class, 2018-2027 (USD Million)
9.1.7.3 UK: Antibiotics Market, by Action Mechanism, 2018-2027 (USD Million)
9.1.8 France: Antibiotics Market - Revenue and Forecast to 2027 (USD Million)
9.1.8.1 France: Antibiotics Market - Revenue and Forecast to 2027 (USD Million)
9.1.8.2 France: Antibiotics Market, by Drug Class, 2018-2027 (USD Million)
9.1.8.3 France: Antibiotics Market, by Action Mechanism, 2018-2027 (USD Million)
9.1.9 Spain: Antibiotics Market - Revenue and Forecast to 2027 (USD Million)
9.1.9.1 Spain: Antibiotics Market - Revenue and Forecast to 2027 (USD Million)
9.1.9.2 Spain: Antibiotics Market, by Drug Class, 2018-2027 (USD Million)
9.1.9.3 Spain: Antibiotics Market, by Action Mechanism, 2018-2027 (USD Million)
9.1.10 Italy: Antibiotics Market - Revenue and Forecast to 2027 (USD Million)
9.1.10.1 Italy: Antibiotics Market - Revenue and Forecast to 2027 (USD Million)
9.1.10.2 Italy: Antibiotics Market, by Drug Class, 2018-2027 (USD Million)
9.1.10.3 Italy: Antibiotics Market, by Action Mechanism, 2018-2027 (USD Million)
10. Impact of COVID-19 Pandemic on Europe Antibiotics Market
10.1 Europe: Impact Assessment of COVID-19 Pandemic
11. Company Profiles
11.1 GlaxoSmithKline plc.
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Sanofi
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Novartis AG
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Bayer AG
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Pfizer Inc.
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
12. Appendix
12.1 About the Publisher
12.2 Glossary of Terms

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • GlaxoSmithKline plc
  • Sanofi
  • Novartis AG
  • Bayer AG
  • Pfizer Inc